Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21069
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOng, Doen Ming-
dc.contributor.authorAshby, Michael-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorGard, Grace-
dc.contributor.authorNg, Zi Y-
dc.contributor.authorHuang, Huayi Ellen-
dc.contributor.authorChong, Yee Shuen-
dc.contributor.authorCheah, Chan Yoon-
dc.contributor.authorDevitt, Bianca-
dc.contributor.authorChong, Geoffrey-
dc.contributor.authorLoh, Zoe-
dc.contributor.authorMo, Allison-
dc.contributor.authorHawkes, Eliza A-
dc.date2019-06-17-
dc.date.accessioned2019-06-24T02:06:08Z-
dc.date.available2019-06-24T02:06:08Z-
dc.date.issued2019-10-
dc.identifier.citationBritish journal of haematology 2019; 187(1): 73-81-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21069-
dc.description.abstractElderly patients may be heterogeneous in their abilities to tolerate immunochemotherapy-associated toxicities. We describe the morbidity of rituximab-chemotherapy combinations among 205 newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients aged ≥60 years from 3 tertiary hospitals between 2009 and 2016, and explore the utility of retrospectively-assigned baseline Comprehensive Geriatric Assessment (CGA) in predicting these toxicities. Seventy-three percent (146/201) experienced grade ≥3 toxicities, 81% (163/201) needed admission, 52% (107/205) had ≥2 unplanned admissions, 82/201 (41%) required dose reductions (DR) subsequent to Cycle 1, 39/166 (23%) had chemotherapy delays and 26/198 (13%) ceased therapy early. CGA was associated with pre-emptive baseline DR and perhaps because of this, did not predict grade ≥3 toxicities, ≥2 unplanned admissions or subsequent DR. Three-year overall survival (OS) of CGA-fit, CGA-unfit and CGA-frail patients was 82%, 60% and 53%, respectively. Three-year progression-free survival (PFS) of CGA-fit, CGA-unfit and CGA-frail patients was 66%, 58% and 46%, respectively. OS of CGA-fit patients was not statistically different from CGA-unfit patients, but was superior to CGA-frail patients (hazard ratio 2·892, 95% confidence interval 1·275-6·559, P = 0·011). PFS differences were not statistically significant. Baseline DR and early therapy cessation were associated with inferior OS and PFS independent of CGA. Prospective studies are needed to confirm if CGA-adapted treatment strategies minimize morbidity and improves survival.-
dc.language.isoeng-
dc.subjectDLBCL-
dc.subjectGeriatric assessment-
dc.subjectelderly-
dc.subjectlymphoma-
dc.subjectmorbidity-
dc.titleComprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.-
dc.typeJournal Article-
dc.identifier.journaltitleBritish journal of haematology-
dc.identifier.affiliationDepartment of Haematology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australiaen
dc.identifier.affiliationMedical School, University of Western Australia, Crawley, Australiaen
dc.identifier.affiliationDepartment of Oncology, Eastern Health, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Haematology, Eastern Health, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Haematology, Pathwest Laboratory Medicine, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationEastern Health Clinical School, Monash University, Melbourne, Australiaen
dc.identifier.doi10.1111/bjh.16049-
dc.identifier.orcid0000-0003-4097-8583-
dc.identifier.orcid0000-0002-9215-1441-
dc.identifier.orcid0000-0002-1923-3133-
dc.identifier.orcid0000-0002-0376-2559-
dc.identifier.pubmedid31206608-
dc.type.austinJournal Article-
local.name.researcherChong, Geoffrey
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
crisitem.author.deptPathology-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.